Jaguar Health Reports Reduced IV Support Needs in Infant Receiving Crofelemer

Key Points

• Jaguar Health reported that an infant with a rare genetic form of intestinal failure needed approximately 15% less daily parenteral support after several weeks of oral crofelemer.
• The patient is receiving treatment through expanded access, not a controlled clinical trial.
• The company also highlighted previously reported reductions in support needs in children with microvillus inclusion disease and short bowel syndrome.
• Jaguar plans to submit an FDA application for crofelemer in microvillus inclusion disease in mid-2027.
• The findings involve very few patients and do not establish broad effectiveness or long-term safety.

Jaguar Health (NASDAQ: JAGX) reported an early benefit from its oral crofelemer formulation in an infant with congenital sodium diarrhea caused by a GUCY2C gene mutation.

According to its subsidiary Napo Pharmaceuticals, the patient’s daily parenteral support—nutrition and fluids delivered intravenously—declined by approximately 15% during the first several weeks of treatment.

Infant’s Early Response Adds to Expanded-Access Findings

Napo said the infant has tolerated treatment without significant clinical or laboratory abnormalities.

The company described this as another intestinal-failure condition in which crofelemer has shown a reduction in support needs, alongside microvillus inclusion disease, or MVID, and short bowel syndrome with intestinal failure, or SBS-IF.

However, this is a single-patient observation without a control group. It cannot establish that crofelemer caused the improvement or predict how other patients will respond.

Earlier Cases Reported Lower Support Needs After More Than a Year

Jaguar also highlighted previously reported findings from three other pediatric patients receiving oral crofelemer.

In one child with MVID, weekly support requirements adjusted for body weight fell by up to 48% after more than 12 months. In two children with SBS-IF, reductions reached up to 40% over a similar period.

These percentages are adjusted for body weight and should not be read as equivalent reductions in total IV volume. The small number of patients also limits conclusions about effectiveness and safety.

MVID Application Is Planned for Mid-2027

Jaguar plans to submit a New Drug Application for crofelemer in MVID in mid-2027. The submission is expected to include results from an ongoing pivotal trial that has completed enrollment.

That filing target concerns MVID—not the infant’s GUCY2C-related condition—and does not guarantee FDA approval.

Investor Takeaway: Encouraging Early Observations, With Pivotal Results Still Important

For JAGX investors, the update adds another patient observation supporting further investigation of crofelemer for rare intestinal-failure conditions.

The more consequential milestones remain the pivotal trial results and the planned FDA submission. The announcement does not establish that the oral formulation is approved for these pediatric uses or that patients can discontinue intravenous support.